Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Sales (2024 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 2 years of Return on Sales data on record, last reported at 5.56% in Q3 2025.

  • For Q3 2025, Return on Sales fell 114.0% year-over-year to 5.56%; the TTM value through Sep 2025 reached 5.56%, down 114.0%, while the annual FY2024 figure was 2.46%, N/A changed from the prior year.
  • Return on Sales reached 5.56% in Q3 2025 per ZNTL's latest filing, up from 6.06% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.25% in Q1 2024 and bottomed at 8.34% in Q1 2025.